2-氟-6-(4-甲基苯氧基)苯甲腈 | 175204-08-7

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟-6-(4-甲基苯氧基)苯甲腈
• 中文别名: 2-氟-6-(4-甲基苯氧基)苯腈
• 英文名称: 2-fluoro-6-(p-tolyloxy)benzonitrile
• 英文别名: 2-Fluoro-6-(4-methylphenoxy)benzonitrile
• CAS: 175204-08-7
• 化学式: C₁₄H₁₀FNO
• mdl: MFCD00068203
• 分子量: 227.238
• InChiKey: JLTWAYPSQIKWIL-UHFFFAOYSA-N

物化性质

• 熔点：
  93-95°C
• 沸点：
  323.0±37.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  2-氟-6-(4-甲基苯氧基)苯甲腈 在 四丁基氟化铵 、 三甲基甲硅烷基锡 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.0h， 生成 2-(2H-tetrazol-5-yl)-3-(p-tolyloxy)benzenesulfonamide
  参考文献：
  名称：

  METALLO-BETA-LACTAMASE INHIBITORS

  摘要：

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。

  公开号：

  US20160333021A1
• 作为产物：
  描述：

  2-氟-6-苯氧基苯甲腈 在 N-甲基吡咯烷酮 、 二氯化双(三环己基膦)镍(II) 、 tris(2,2-bipyridine)ruthenium(II) hexafluorophosphate 、 C₂₀H₂₈N₄O₂Pd⁽²⁺⁾*2BF₄^(1-) 、 四丁基氯化铵 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 44.0h， 生成 2-氟-6-(4-甲基苯氧基)苯甲腈
  参考文献：
  名称：

  芳烃的选择性甲基化：自由基C H功能化/交叉耦合序列

  摘要：

  已经开发出一种选择性的，非螯合辅助的芳烃甲基化方法。整体转化结合了CH官能化反应和镍催化的交叉偶联，可快速获得具有高对位选择性的甲基化芳烃。该反应适合小分子药物的后期甲基化。

  DOI：

  10.1002/anie.201804628

文献信息

• [EN] METALLO-BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015112441A1

  公开（公告）日：2015-07-30

  The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。
• Direct Dehydrogenative Access to Unsymmetrical Phenones
  作者：Congjun Yu、Raolin Huang、Frederic W. Patureau

  DOI：10.1002/anie.202201142

  日期：2022.5.9

  The Friedel–Crafts reaction is an emblematic method for constructing C−C bonds at aromatic positions. Rendering this reaction dehydrogenative on a broad scope of substrates under simple reaction conditions constitutes an important milestone for synthetic chemistry.

  弗里德尔-克来福特反应是在芳香位置构建 C−C 键的标志性方法。在简单的反应条件下使该反应在广泛的底物上发生脱氢，是合成化学的一个重要里程碑。
• Monoamine reuptake inhibitors for treatment of CNS disorders
  申请人：——

  公开号：US20020143003A1

  公开（公告）日：2002-10-03

  The present invention relates to compounds of the formula 1 wherein R 1 through R 4 , X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

  本发明涉及公式1的化合物，其中R1至R4、X、Y、m和n的定义如规范中所述。这些化合物有用，能够表现出作为血清素、去甲肾上腺素和多巴胺再摄取抑制剂的活性，以及其药学上可接受的盐，并且它们在中枢神经系统和其他疾病的治疗中使用。
• Synthesis and Biological Evaluation of Novel 2,4-Diaminoquinazoline Derivatives as <i>SMN2</i> Promoter Activators for the Potential Treatment of Spinal Muscular Atrophy
  作者：John Thurmond、Matthew E. R. Butchbach、Marty Palomo、Brian Pease、Munagala Rao、Louis Bedell、Monica Keyvan、Grace Pai、Rama Mishra、Magnus Haraldsson、Thorkell Andresson、Gisli Bragason、Margret Thosteinsdottir、Jon Mar Bjornsson、Daniel D. Coovert、Arthur H. M. Burghes、Mark E. Gurney、Jasbir Singh

  DOI：10.1021/jm061475p

  日期：2008.2.1

  Proximal spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by death of motor neurons in the spinal cord that is caused by deletion and/or mutation of the survival motor neuron gene (SMN1). Adjacent to SMN1 are a variable number of copies of the SMN2 gene. The two genes essentially differ by a single nucleotide, which causes the majority of the RNA transcripts from SMN2 to lack exon 7. Although both SMN1 and SMN2 encode the same Smn protein amino acid sequence, the loss of SMN1 and incorrect splicing of SMN2 have the consequence that Smn protein levels are insufficient for the survival of motor neurons. The therapeutic goal of our medicinal chemistry effort was to identify small-molecule activators of the SMN2 promoter that, by up-regulating gene transcription, would produce greater quantities of full-length Smn protein. Our initial medicinal chemistry effort explored a series of C5 substituted benzyl ether based 2,4-diaminoquinazoline derivatives that were found to be potent activators of the SMN2 promoter; however, inhibition of DHFR was shown to be an off-target activity that was linked to ATP depletion. We used a structure-guided approach to overcome DHFR inhibition while retaining SMN2 promoter activation. A lead compound 11a was identified as having high potency (EC50 = 4 nM) and 2.3-fold induction of the SMN2 promoter. Compound Ila possessed desirable pharmaceutical properties, including excellent brain exposure and long brain half-life following oral dosing to mice. The piperidine compound Ila up-regulated expression of the mouse SMN gene in NSC-34 cells, a mouse motor neuron hybrid cell line. In type I SMA patient fibroblasts, compound Ila induced Smn in a dose-dependent manner when analyzed by immuno-blotting and increased the number of intranuclear particles called gems. The compound restored gems numbers in type I SMA patient fibroblasts to levels near unaffected genetic carriers of SMA.
• INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE
  申请人：Pfizer Products Inc.

  公开号：EP1154984A1

  公开（公告）日：2001-11-21